Aslan Pharma's drug candidate for bile duct cancer gets US FDA orphan drug status

13 August 2015

Biotechnology firm Aslan Pharmaceuticals on Thursday said its drug candidate for bile duct cancer, its lead compound ASLAN001, has been assigned orphan drug designation by the US Food and Drug Administration.

The Singapore-based company, focussed on oncology, said that ASLAN001 is currently in mid-stage trial, Phase II studies in breast cancer and cholangiocarcinoma. Studies in gastric cancer are also being planned. Orphan drug status will provide Aslan incentives including extended marketing exclusivity to develop the drug in cholangiocarcinoma.

Chief executive Carl Firth, said: "In addition to our work in cholangiocarcinoma, we are progressing our portfolio of immunotherapies and targeted agents in other Asia prevalent tumour types, including gastric cancer and hepatocellular carcinoma."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK